Marksans Pharma Limited
Symbool: MARKSANS.NS
NSE
158.25
INRMarktprijs vandaag
22.7836
Koers/Winst Verhouding
0.5408
Koers/Winst Groei Verhouding
71.71B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Marksans Pharma Limited (MARKSANS-NS) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 27678.4 | 7191.6 | 3466.9 | 2093.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 34038.7 | 3367.2 | 4.3 | 17.2 | |||||||||||||||||||
balance-sheet.row.net-receivables | 8696.08 | 4187.6 | 4115.6 | 2767.3 | |||||||||||||||||||
balance-sheet.row.inventory | 10153.42 | 4847.4 | 4244.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 1029.74 | 526.4 | 185.1 | 118.2 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 47557.64 | 16753 | 12012 | 9022.5 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 8581.34 | 3868.9 | 3422.9 | 2540.2 | |||||||||||||||||||
balance-sheet.row.goodwill | 771.91 | 384.9 | 300.3 | 195.9 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1395.4 | 708 | 585.7 | 474.4 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2167.31 | 1092.9 | 885.9 | 670.2 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -6433 | -3332.4 | -62 | 8.4 | |||||||||||||||||||
balance-sheet.row.tax-assets | 6517.3 | 3375.9 | 38.6 | 8 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | -13350.95 | 145.7 | 103.7 | 33.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | -2518 | 5150.9 | 4389 | 3260 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 45039.64 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.account-payables | 4309.35 | 2306 | 2000.8 | 1686.6 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 1073.1 | 572.6 | 693.4 | 247.8 | |||||||||||||||||||
balance-sheet.row.tax-payables | 667.33 | 252.8 | 173.3 | 300.2 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 1267.38 | 656.9 | 414.3 | 93.3 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 121.1 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 321.13 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 376.6 | 112.4 | 543 | 639.3 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1681.51 | 843.3 | 609.1 | 245 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 1572.51 | 813.6 | 694.9 | 153.6 | |||||||||||||||||||
balance-sheet.row.total-liab | 8418.8 | 4253.2 | 4171.3 | 3229 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 13274.17 | 13274.2 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 906.32 | 453.2 | 409.3 | 409.3 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 10913.4 | 10913.4 | 5093.1 | 3349.3 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 58687.73 | 4177.4 | 4788.4 | 3355 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | -10953.25 | -11366.6 | 1731.9 | 1751.3 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 72828.37 | 17451.6 | 12022.7 | 8864.9 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 81660.48 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.minority-interest | 413.31 | 199.1 | 207 | 188.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 73241.68 | 17650.7 | 12229.7 | 9053.5 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 81660.48 | - | - | - | |||||||||||||||||||
Total Investments | 27605.7 | 34.8 | 26.1 | 25.6 | |||||||||||||||||||
balance-sheet.row.total-debt | 2340.48 | 1229.5 | 1107.8 | 341 | |||||||||||||||||||
balance-sheet.row.net-debt | 8700.78 | -2594.9 | -2354.8 | -1752.8 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3181.21 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1114.7 | -1107 | -1500.3 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | -275.2 | -1039.3 | -367.4 | |||||||||||||||||
cash-flows.row.inventory | 0 | -448.5 | -178.5 | -1624.8 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 224.2 | 184.9 | 417.8 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -615.2 | -74.1 | 74.1 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -3181.21 | -406.3 | -823.3 | -95.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1343.16 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -266.1 | 0.3 | 5.2 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -1897.7 | -1.5 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2163.8 | -0.3 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | -2055.8 | 47.9 | 10.1 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2592.1 | -416.9 | -449 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2295.4 | -225.5 | -1 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 2747.1 | 911.5 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -451.7 | -225.5 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -101.7 | -105.8 | -40.9 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 2080 | 440.4 | -110.9 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 1978.3 | 795.1 | -152.9 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -1428.6 | -1 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 1343.16 | 1760.3 | 1370.8 | 1185.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 21580.94 | 3824.4 | 3492.7 | 2122.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 20237.78 | 2064.1 | 2121.8 | 937.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 1343.16 | 2374.1 | 992.6 | 1787.4 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.free-cash-flow | 1343.16 | 1837.8 | 529.3 | 1323.2 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 21033.72 | 18521.4 | 14801.2 | 13683.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 10121.39 | 9213.6 | 7480.2 | 6186 | |||||||||||||||||||
income-statement-row.row.gross-profit | 10912.33 | 9307.8 | 7321.1 | 7497.8 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 283.89 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 6999.05 | 6433.1 | 5153.7 | 4310.6 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 17120.44 | 15646.7 | 12633.9 | 10496.6 | |||||||||||||||||||
income-statement-row.row.interest-income | 158.31 | 59.4 | 59.7 | 11.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 5033.87 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 4261.33 | 2877.3 | 2141 | 3092.2 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 4274.26 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 1074.63 | 723.3 | 607 | 636.3 | |||||||||||||||||||
income-statement-row.row.net-income | 3173.43 | 2663.1 | 1845.7 | 2385.4 |
Vaak gestelde vragen
Wat is Marksans Pharma Limited (MARKSANS.NS) totale activa?
Marksans Pharma Limited (MARKSANS.NS) totale activa is 21903890000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 11173630000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.519.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.151.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.203.
Wat is Marksans Pharma Limited (MARKSANS.NS) nettowinst (netto-inkomen)?
De nettowinst is 2663080000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1229450000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 6433130000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is -6611350000.000.